CN108025019A - Blood glucose value raises inhibitor and the oral composition containing it - Google Patents
Blood glucose value raises inhibitor and the oral composition containing it Download PDFInfo
- Publication number
- CN108025019A CN108025019A CN201680053826.1A CN201680053826A CN108025019A CN 108025019 A CN108025019 A CN 108025019A CN 201680053826 A CN201680053826 A CN 201680053826A CN 108025019 A CN108025019 A CN 108025019A
- Authority
- CN
- China
- Prior art keywords
- glucose
- alpha
- glucans
- mixture
- branch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 title claims abstract description 285
- 239000008103 glucose Substances 0.000 title claims abstract description 282
- 239000000203 mixture Substances 0.000 title claims abstract description 182
- 239000008280 blood Substances 0.000 title claims abstract description 147
- 210000004369 blood Anatomy 0.000 title claims abstract description 147
- 239000003112 inhibitor Substances 0.000 title claims abstract description 64
- 229920000310 Alpha glucan Polymers 0.000 claims abstract description 147
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract description 100
- 150000002772 monosaccharides Chemical class 0.000 claims abstract description 59
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims abstract description 50
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims abstract description 50
- 238000006116 polymerization reaction Methods 0.000 claims abstract description 49
- 235000000346 sugar Nutrition 0.000 claims abstract description 34
- 229920001503 Glucan Polymers 0.000 claims abstract description 32
- 238000000034 method Methods 0.000 claims description 44
- 235000013325 dietary fiber Nutrition 0.000 claims description 24
- 239000004480 active ingredient Substances 0.000 claims description 18
- 239000007787 solid Substances 0.000 claims description 14
- 239000007788 liquid Substances 0.000 claims description 11
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 9
- 229930091371 Fructose Natural products 0.000 claims description 8
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims description 8
- 238000004128 high performance liquid chromatography Methods 0.000 claims description 8
- 239000005715 Fructose Substances 0.000 claims description 7
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 3
- 108010001682 Dextranase Proteins 0.000 claims description 3
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 3
- 230000036541 health Effects 0.000 abstract description 2
- 239000000047 product Substances 0.000 description 48
- 210000000813 small intestine Anatomy 0.000 description 39
- 235000013305 food Nutrition 0.000 description 30
- 239000000843 powder Substances 0.000 description 28
- 229920001353 Dextrin Polymers 0.000 description 26
- 239000004375 Dextrin Substances 0.000 description 26
- 235000019425 dextrin Nutrition 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 26
- 244000269722 Thea sinensis Species 0.000 description 22
- 238000012360 testing method Methods 0.000 description 22
- 230000011987 methylation Effects 0.000 description 19
- 238000007069 methylation reaction Methods 0.000 description 19
- 230000000694 effects Effects 0.000 description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 15
- 102000004190 Enzymes Human genes 0.000 description 14
- 108090000790 Enzymes Proteins 0.000 description 14
- 235000006468 Thea sinensis Nutrition 0.000 description 14
- 235000013361 beverage Nutrition 0.000 description 14
- 235000020279 black tea Nutrition 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 14
- 206010012601 diabetes mellitus Diseases 0.000 description 13
- 239000007789 gas Substances 0.000 description 13
- 230000005764 inhibitory process Effects 0.000 description 13
- 230000009967 tasteless effect Effects 0.000 description 12
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 11
- 229920002472 Starch Polymers 0.000 description 10
- 230000029087 digestion Effects 0.000 description 10
- -1 glucitol acetic acid esters Chemical class 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 235000019698 starch Nutrition 0.000 description 10
- 239000008107 starch Substances 0.000 description 10
- 240000007154 Coffea arabica Species 0.000 description 9
- 235000016213 coffee Nutrition 0.000 description 9
- 235000013353 coffee beverage Nutrition 0.000 description 9
- 239000013068 control sample Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 235000015067 sauces Nutrition 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 235000013616 tea Nutrition 0.000 description 8
- 108010073178 Glucan 1,4-alpha-Glucosidase Proteins 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 229960002737 fructose Drugs 0.000 description 7
- 210000004400 mucous membrane Anatomy 0.000 description 7
- 229920001542 oligosaccharide Polymers 0.000 description 7
- 150000002482 oligosaccharides Chemical class 0.000 description 7
- 235000019605 sweet taste sensations Nutrition 0.000 description 7
- 102100022624 Glucoamylase Human genes 0.000 description 6
- 235000009754 Vitis X bourquina Nutrition 0.000 description 6
- 235000012333 Vitis X labruscana Nutrition 0.000 description 6
- 240000006365 Vitis vinifera Species 0.000 description 6
- 235000014787 Vitis vinifera Nutrition 0.000 description 6
- 235000012970 cakes Nutrition 0.000 description 6
- 239000004033 plastic Substances 0.000 description 6
- 229920003023 plastic Polymers 0.000 description 6
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 5
- 235000015895 biscuits Nutrition 0.000 description 5
- 239000007853 buffer solution Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000009508 confectionery Nutrition 0.000 description 5
- 239000006071 cream Substances 0.000 description 5
- 235000011950 custard Nutrition 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000002845 discoloration Methods 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000001629 suppression Effects 0.000 description 5
- 241000209140 Triticum Species 0.000 description 4
- 235000021307 Triticum Nutrition 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 4
- 230000004190 glucose uptake Effects 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 239000007937 lozenge Substances 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 235000014347 soups Nutrition 0.000 description 4
- 239000000052 vinegar Substances 0.000 description 4
- 235000021419 vinegar Nutrition 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 3
- 229920002774 Maltodextrin Polymers 0.000 description 3
- 239000005913 Maltodextrin Substances 0.000 description 3
- 240000007594 Oryza sativa Species 0.000 description 3
- 235000007164 Oryza sativa Nutrition 0.000 description 3
- 108090000992 Transferases Proteins 0.000 description 3
- 102000004357 Transferases Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 229940099112 cornstarch Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 150000002016 disaccharides Chemical class 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 229940035034 maltodextrin Drugs 0.000 description 3
- LGRLWUINFJPLSH-UHFFFAOYSA-N methanide Chemical compound [CH3-] LGRLWUINFJPLSH-UHFFFAOYSA-N 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 230000000291 postprandial effect Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 235000009566 rice Nutrition 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 235000013599 spices Nutrition 0.000 description 3
- 238000012795 verification Methods 0.000 description 3
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 2
- 239000004382 Amylase Substances 0.000 description 2
- 108010065511 Amylases Proteins 0.000 description 2
- 102000013142 Amylases Human genes 0.000 description 2
- 241000186074 Arthrobacter globiformis Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000193752 Bacillus circulans Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 235000005979 Citrus limon Nutrition 0.000 description 2
- 244000131522 Citrus pyriformis Species 0.000 description 2
- 108010025880 Cyclomaltodextrin glucanotransferase Proteins 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 108010028688 Isoamylase Proteins 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 2
- 240000001417 Vigna umbellata Species 0.000 description 2
- 235000011453 Vigna umbellata Nutrition 0.000 description 2
- 102000004139 alpha-Amylases Human genes 0.000 description 2
- 108090000637 alpha-Amylases Proteins 0.000 description 2
- 229940024171 alpha-amylase Drugs 0.000 description 2
- 235000019418 amylase Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 239000007894 caplet Substances 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 235000021185 dessert Nutrition 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 229960001031 glucose Drugs 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 230000008676 import Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003456 ion exchange resin Substances 0.000 description 2
- 229920003303 ion-exchange polymer Polymers 0.000 description 2
- 125000003153 isomaltose group Chemical group 0.000 description 2
- 150000002525 isomaltoses Chemical class 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 229920001206 natural gum Polymers 0.000 description 2
- 235000012149 noodles Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 235000012771 pancakes Nutrition 0.000 description 2
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 235000013824 polyphenols Nutrition 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MIDXCONKKJTLDX-UHFFFAOYSA-N 3,5-dimethylcyclopentane-1,2-dione Chemical compound CC1CC(C)C(=O)C1=O MIDXCONKKJTLDX-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241001474374 Blennius Species 0.000 description 1
- 241000345998 Calamus manan Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 208000003643 Callosities Diseases 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 240000008067 Cucumis sativus Species 0.000 description 1
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 1
- 241000732800 Cymbidium Species 0.000 description 1
- BJHIKXHVCXFQLS-PUFIMZNGSA-N D-psicose Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)C(=O)CO BJHIKXHVCXFQLS-PUFIMZNGSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 206010018612 Gonorrhoea Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 239000004376 Sucralose Substances 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 238000010162 Tukey test Methods 0.000 description 1
- LUEWUZLMQUOBSB-UHFFFAOYSA-N UNPD55895 Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(OC3C(OC(O)C(O)C3O)CO)C(O)C2O)CO)C(O)C1O LUEWUZLMQUOBSB-UHFFFAOYSA-N 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 1
- 230000000397 acetylating effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- WQZGKKKJIJFFOK-DVKNGEFBSA-N alpha-D-glucose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-DVKNGEFBSA-N 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000004411 aluminium Substances 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000010612 desalination reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 235000012489 doughnuts Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002168 ethanoic acid esters Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000011706 ferric diphosphate Substances 0.000 description 1
- 235000007144 ferric diphosphate Nutrition 0.000 description 1
- CADNYOZXMIKYPR-UHFFFAOYSA-B ferric pyrophosphate Chemical compound [Fe+3].[Fe+3].[Fe+3].[Fe+3].[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O.[O-]P([O-])(=O)OP([O-])([O-])=O CADNYOZXMIKYPR-UHFFFAOYSA-B 0.000 description 1
- 229940036404 ferric pyrophosphate Drugs 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 150000002303 glucose derivatives Chemical class 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 235000001497 healthy food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000007031 hydroxymethylation reaction Methods 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 238000006317 isomerization reaction Methods 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- UYQJCPNSAVWAFU-UHFFFAOYSA-N malto-tetraose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)O1 UYQJCPNSAVWAFU-UHFFFAOYSA-N 0.000 description 1
- LUEWUZLMQUOBSB-OUBHKODOSA-N maltotetraose Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O[C@@H]3[C@@H](O[C@@H](O)[C@H](O)[C@H]3O)CO)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-OUBHKODOSA-N 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 235000012459 muffins Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000015145 nougat Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 235000012434 pretzels Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 235000012950 rattan cane Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940079827 sodium hydrogen sulfite Drugs 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000011497 sour milk drink Nutrition 0.000 description 1
- 235000013322 soy milk Nutrition 0.000 description 1
- 235000013555 soy sauce Nutrition 0.000 description 1
- 235000011496 sports drink Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 1
- 235000019408 sucralose Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 125000000647 trehalose group Chemical group 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000012773 waffles Nutrition 0.000 description 1
- 230000005428 wave function Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23F—COFFEE; TEA; THEIR SUBSTITUTES; MANUFACTURE, PREPARATION, OR INFUSION THEREOF
- A23F3/00—Tea; Tea substitutes; Preparations thereof
- A23F3/16—Tea extraction; Tea extracts; Treating tea extract; Making instant tea
- A23F3/163—Liquid or semi-liquid tea extract preparations, e.g. gels, liquid extracts in solid capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
The present invention is intended to provide the people of the people containing health and care about blood glucose value can be daily easy and safely, and the blood glucose value rise inhibitor after the monosaccharide intake constantly absorbed and the oral composition containing it.The present invention is by providing (A) using glucose as being formed sugar, (B) have through α 1, key connection beyond 4 keys is to positioned at through α 1, the branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of the straight-chain glucan of the glucose polymerization degree more than 3 of 4 key connections, the blood glucose value that (C) contains the branch's alpha-glucan mixture for digesting generation isomaltose by isomaltose glucanase raise inhibitor and together raise the oral composition of inhibitor containing above-mentioned blood glucose value with monosaccharide and solve.
Description
【Technical field】
The present invention relates to blood glucose value to raise inhibitor, in particular to the liter for suppressing the blood glucose value after monosaccharide absorbs
High blood glucose value rise inhibitor and, containing its oral composition.
【Background technology】
In advanced state, the increase of diabetes becomes big social concern, its prevention becomes big problem.In order to prevent or
Improve diabetes, recommend the aerobic exercise of control, walking or the running of the amount of having dinner etc., but these are grown under suitable guidance
Period, daily carry out being difficult.
Generally, it is believed that the state for maintaining blood glucose value high easily becomes diabetes, particularly, suppress just feeding
Blood glucose value afterwards, the rise of so-called postprandial plasma glucose level are important for diabetes mellitus prevention.But in recent years, make as monosaccharide
Isomerized sugar obtained from a kind of glucose isomerization (mixture of glucose and fructose) becomes as sweetening material in various foods
Widely use in thing, especially taken the photograph compared with cold drink etc. in large quantities in use, although being unaware that through the intake of beverage
The chance of monosaccharide is taken to become more.The monosaccharide of glucose or fructose etc. is since intake is absorbed with being easy for and causes blood glucose value
Raise, the blood glucose value rise after food of the suppression intake containing these monosaccharides is also important from the viewpoint of prevention diabetes.
Under such situation, the elevated method as the blood glucose value after easily controlling monosaccharide to absorb, it is proposed that utilize
The method that the elevated material for then suppressing blood glucose value is together absorbed with monosaccharide.For example, Patent Document 1 discloses from big
Blood glucose value rise of the wheat germ breast when obtained β -1,3-1,4- glucans suppress glucose load.But such as in non-patent text
Reported in offering 1, β -1,3-1,4- glucans are in impaired glucose tolerance, are had only on the difficult people reduced of blood glucose value, so-called " diabetes side
Blood glucose value when glucose load is played in the case of the people in battery limit (BL) domain " raises the limitation of inhibition.In addition, in patent document
Disclosed in 2, rat together absorbs the D-Psicose of high-purity with glucose, then blood glucose value rise is suppressed.But D- Ah
Lip river ketose is since itself is pleasantly sweet, not only can not be accessible to flavor influence when being applied in combination with pleasantly sweet monose
Ground utilizes, and is also unsuitable for it is expected the cooperation such as the tasteless tea beverage for taking agent or sugar-free, approximate water, as there is blood glucose value rise
The dry beverage of inhibition, in the embodiment that can not be applied to utilize before and after the food containing monosaccharide is absorbed
Point, utilization scope has boundary.
On the one hand, indigestible dextrins, add a small amount of inorganic acid after, process obtained from the roasting dextrin of heating
A kind of indigestible dextrins (non-patent literature 2) as water-soluble dietary fiber have suppression due to itself being low sweet taste
The rise of postprandial plasma glucose level, makes the stable effect of the secretion of insulin, coordinates with more food, utilizes, but the indigestible
Dextrin such as reports that inhibition is not shown in the rise of the blood glucose value after being absorbed for monosaccharide in non-patent literature 3 and 4.
In this way, although the monosaccharide of isomerized sugar etc. is under the situation used as sweetening material in various beverages, mesh
Before, there is suppression to be not only " people of diabetes borderline region ", also including other people people absorb isomerized sugar etc. monosaccharide it
The elevated effect of blood glucose value afterwards, can be daily easy and safely while itself being low sweet taste~tasteless, Er Qieji
The blood glucose value of continuous intake raises inhibitor according to known to the present inventor, has not been reported.
【Prior art literature】
【Patent document】
Patent document 1:Special open 2009-263655 publications
Patent document 2:Special open 2005-213227 publications
【Non-patent literature】
Non-patent literature 1:8th time big wheat food forum, on October 23rd, 2012
Non-patent literature 2:" starch chemistry ", volume 37, No. 2, the 107-114 pages (1990)
Non-patent literature 3:If woods etc., Japanese nutrition-grain association will, volume 46, No. 2, the 131-137 pages
(1993)
Non-patent literature 4:If woods etc., Japanese food fiber research can will, volume 3, No. 1, the 13-19 pages (1999)
【The content of the invention】
【The invention technical task to be solved】
The present invention is intended to provide it is not limited to " people of diabetes borderline region " and has the blood of the people after suppressing monosaccharide intake
The elevated effect of sugar value, itself is extensive to tasteless utilization scope with low sweet taste, can be daily easy and safely continues
The blood glucose value rise inhibitor of intake and the oral composition containing it.
【Solve the technical solution of problem】
For solve the above subject repeat it is that sharp study is made great efforts as a result, the inventors discovered that, the applicant is previously in state
Border discloses branch's alpha-glucans mixture disclosed in WO2008/136331 separate editions, specifically, using glucose as
Sugar is formed, in the non-reducing end glucose residue of the straight-chain glucan of the glucose polymerization degree more than 3 through α-Isosorbide-5-Nitrae key connection
On have the branched structure of the glucose polymerization degree more than 1 through the key connection beyond α-Isosorbide-5-Nitrae key, digested by isomaltose glucanase
Branch's alpha-glucans mixture of isomaltose is generated, unexpectedly, not only suppresses the rise of postprandial plasma glucose level, also suppresses single
The rise of blood glucose value after carbohydrate intake.Such opinion is complete unexpected opinion.The reason is that, due to above-mentioned branched alpha-
Glucan mixture is the polymer for the glucose for having branch, in the point of display water-soluble dietary fiber is pasted with indigestible
The mixture of the similar starch source of essence, in the same manner as the indigestible dextrins reported in non-patent literature 3 and 4, is considered pair
Blood glucose value rise after monosaccharide intake does not show inhibition.However, people is by experimental verification, above-mentioned branch according to the present invention
Alpha-glucans mixture, if people is absorbed, is not limited to " people of diabetes borderline region ", the blood glucose after monosaccharide intake
The rise of value is significantly suppressed.Based on this new opinion, the present inventor establishes, itself is with low sweet taste to tasteless utilization scope
Widely, " people of diabetes borderline region " effect is not limited to, the elevated blood for having the blood glucose value after suppressing monosaccharide intake
Sugar value rise inhibitor and the oral composition containing it, thereby completing the present invention.
That is, the present invention is by providing to there is branch's alpha-glucans mixture of the feature of following (A) or even (C) as effectively
Blood glucose value after the monosaccharide intake of component raises inhibitor and solves above-mentioned problem.
(A) using glucose as being formed sugar,
(B) have through the key connection beyond α -1,4 keys to positioned at the straight of the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of chain glucan,
(C) generation isomaltose is digested by isomaltose glucanase.
The branch's alpha-glucans mixture for having features described above is not only the safe edibility raw material of worry without side-effects,
Low sweet taste~tasteless, when together being absorbed with monosaccharide, there is the elevated effect for the blood glucose value for suppressing people.So as to there is features described above
(A) so (C) branch's alpha-glucans mixture as monosaccharide absorb after blood glucose value rise inhibitor active ingredient pole
It is useful.
Furthermore by providing, together oral composition containing monosaccharide solves the present invention with above-mentioned blood glucose value rise inhibitor
Certainly above-mentioned problem.
【Invention effect】
For the blood glucose value rise inhibitor of the present invention due to itself being low sweet taste~tasteless, utilization scope is extensive, can be unlimited
Suppress the blood glucose value rise after monosaccharide intake in " people of diabetes borderline region ".In addition, the oral composition of the present invention
Since the blood glucose value containing the present invention raises inhibitor, it easy and safely can effectively suppress intake monosaccharide by absorbing it
The rise of blood glucose value afterwards.
【Brief description of the drawings】
【Fig. 1】Be show make subject intake be only made of glucose control sample when, and intake with glucose together
During test specimens containing branch's alpha-glucans mixture, the average value of the increment of the blood glucose value in subject through time-varying
The figure of change.
【Fig. 2】It has been displayed as the figure of the summary of the device made using the glucose absorption experiment of reversion small intestine.
【Embodiment】
The present invention is to be related to using the branch's alpha-glucans mixture for having the feature of following (A) or even (C) to be used as active ingredient
Blood glucose value rise inhibitor invention.
(A) using glucose as being formed sugar,
(B) have through the key beyond α -1,4 keys and be connected to and be located at the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of straight-chain glucan,
(C) generation isomaltose is digested by isomaltose glucanase.
Described blood glucose value rise inhibitor refers to suppress the liter of the blood glucose value after the monosaccharide intake of people in this specification
High agent.
Furthermore described intake refers to that people is taken into vivo in this specification, containing the intake by peroral route and by through pipe way
Both the intake in footpath.
The blood glucose value rise inhibitor of the present invention preferably absorbs at the same time or before and after phase with monosaccharide.
The present invention blood glucose value rise inhibitor be as active ingredient contain above-mentioned branch's alpha-glucans mixture (with
Under, it is known as " this branch alpha-glucans mixture ") form.This branch alpha-glucans mixture, as described later, can be by various systems
The method of making obtains, and obtained this branch alpha-glucans mixture has been generally in various branched structures and glucose and has gathered
The form of the mixture of most branch's alpha-glucanses of right (molecular weight), in existing technology, is divided one by one
Branch alpha-glucans isolated is quantitatively impossible.Therefore, although can not be determined with the per molecule of branch's alpha-glucans every kind of
The structure of branch's alpha-glucans, i.e., as the bonding pattern of the glucose residue of Component units and bonding order, but this branched alpha-
The structure of glucan mixture can be made by the method for the method of the various physics generally used in this area, chemical method or enzyme
For mixture general token.
Specifically, the structure of this branch alpha-glucans mixture, it is overall as mixture, by above-mentioned (A) or even (C)
Characteristic present.That is, this branch alpha-glucans mixture is using glucose as the glucan (feature (A)) for being formed sugar, have through α-
Key beyond 1,4 keys and the one end for being connected to the straight-chain glucan positioned at the glucose polymerization degree more than 3 through α -1,4 key connections
Non-reducing end glucose residue glucose polymerization degree more than 1 branched structure (feature (B)).Furthermore institute in feature (B)
Among " the non-reducing end glucose residue " said refers to the dextran chain through α-Isosorbide-5-Nitrae key connection, positioned at the end for not showing reproducibility
The glucose residue at end, " key beyond α-Isosorbide-5-Nitrae key " as its name suggests, refer to the key beyond α-Isosorbide-5-Nitrae key.
Furthermore this branch alpha-glucans mixture digests generation isomaltose (feature (C)) by isomaltose glucanase.
The digestion of described isomaltose glucanase is to instigate isomaltose glucanase to act on this branch alpha-glucans in feature (C)
Mixture and hydrolyze.Isomaltose glucanase is to confer to the enzyme of enzyme number (EC) 3.2.1.94, even being to have to gather with α-Portugal
Any bonding sample of α -1,2, α -1,3, α -1,4 and α -1,6 keys that the reduction end side of isomaltose structure in sugar abuts
The enzyme for the feature that formula hydrolyzes.Preferably, using the different wheat in Arthrobacter globiformis (Arthrobacter globiformis) source
Bud sugar dextranase (see, for example, Sawai et al., Agricultural and Biological Chemistry, volume 52,
No. 2, page 495 page -501 (1988)).
Represented by the ratio of the isomaltose of every solids of the digest of isomaltose glucanase digestion generation in structure
Into the different malt that can be hydrolyzed by isomaltose glucanase in the structure of branch's alpha-glucans of branch's alpha-glucans mixture
The ratio of sugared structure, can be by feature (C), using the structure of this branch alpha-glucans mixture as mixture entirety, by the side of enzyme
Method characterizes.
This branch alpha-glucans mixture is digested by isomaltose glucanase, with every solids of digest, in general, 5
Below 70 mass % of more than quality %, are preferably, below 60 mass % of more than 10 mass %, more preferably more than 20 mass % 50
Below quality % generates isomaltose, and the blood glucose value rise inhibition after being absorbed by monosaccharide is considered excellent, so as to be fitted
Preferably use.
I.e., as described later, it is believed that this branch alpha-glucans mixture has generates different wheat by isomaltose glucanase digestion
The feature of the structure of bud sugar and the rise inhibition of the blood glucose value after the monosaccharide intake by this branch alpha-glucans mixture
It is deep related.That is, branch alpha-glucans of the isomaltose growing amount less than 5 mass % in isomaltose glucanase digestion
Mixture is as the feature for having the structure close to the few maltodextrin of branched structure, on the contrary, in isomaltose glucan
Isomaltose growing amount in enzymic digestion surpass 70 mass % branch's alpha-glucans mixture become have close to as with α -1,6
The feature of the structure of the glucan of the glucose polymer of key connection, due to being tied in branch specified in above-mentioned feature (B)
Structure tails off, and the rise for being considered the blood glucose value after being absorbed with monosaccharide in the case of whole suppresses the feature of relevant structure gradually
Weak, there are optimum range for the amount of the isomaltose digested by isomaltose glucanase.
In addition, the embodiment preferably as this branch alpha-glucans mixture, can enumerate by efficient liquid phase
The water-soluble dietary fiber content that chromatograph (enzyme-HPLC methods) is obtained is feature (D) more than 40 mass %.
Obtain water-soluble dietary fiber content " high-performance liquid chromatograph method (enzyme-HPLC methods) " (hreinafter referred to as " enzyme-
HPLC methods ".) refer to that the nutrition in May, 1996 Health and human services department bulletin the 146th represents the benchmark, " analysis method of nutritional ingredient etc.
Deng (nutrition represents the method shown in benchmark other the 1st the 3rd column of table) " in the 8th, in the method described in " food fiber ", it is right
Its outline illustrates then as follows.That is, by by sample by utilizing Thermostable aamylase, protease and glucoamylase
A series of enzymatic treatment resolution process, by ion exchange resin from treatment fluid remove protein, organic acid, inorganic salts and modulate
The sample solution of gel permeation chromatography.Next, for gel permeation chromatography, obtain in chromatogram do not digest glucan and
The peak area of glucose, respective peak area, and separately, by conventional method, use the examination obtained by glucose-oxidase method
Glucose amount in sample solution and calculate the water-soluble dietary fiber content of sample.It is furthermore in this specification in the whole text, " water-soluble
Food fiber content ", as long as without special instruction, just refers to be contained by the water-soluble dietary fiber that above-mentioned " enzyme-HPLC methods " is obtained
Amount.
Water-soluble dietary fiber content represents the content for the alpha-glucans not decomposed by alpha-amylase and glucoamylase,
Feature (D) be by the structure of this branch alpha-glucans mixture, it is overall as mixture, the index characterized by the method for enzyme it
One.
Furthermore as noted above it is believed that by isomaltose glucanase digest generation isomaltose structure feature with by
The rise inhibition of blood glucose value after the monosaccharide intake of this branch alpha-glucans mixture is deeply related, the knot of this characteristic
Structure part, certainly, the water-soluble dietary fiber content of this branch alpha-glucans mixture are higher, in other words, not by alpha-amylase
It is just more and the content of branch's alpha-glucans of glucoamylase decomposition is more, it is not digested and reaches small intestine, is considered showing
The rise inhibitory action of blood glucose value.So as to this branched alpha-Portugal as the active ingredient of the blood glucose value rise inhibitor of the present invention
Oligosaccharide mixture, water-soluble dietary fiber content is more high the more preferred, and suitable water-soluble dietary fiber content is typically 40 matter
More than % is measured, is further preferably more than 75 mass % more preferably more than 60 mass %.Suitable water-soluble dietary fiber content it is upper
Limit is not particularly limited, if technically may, it is the higher the better, be preferably below 100 mass % or less than 100 mass %.
Furthermore as an embodiment preferably for this branch alpha-glucans mixture, there are following characteristics (E) and (F)
Branch's alpha-glucans mixture, the feature can obtain by methylation analysis.
(E) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is in 1:0.6~1:4 scope,
(F) the total of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys accounts for the 55% of full glucose residue
More than.
Methylation analysis, such as it is well known that referring in polysaccharide or oligosaccharides, the bonding sample as definite its monose of composition
The method of formula generally widely used method (Ciucanu et al., Carbohydrate Research, volume 131, No. 2,
209-217 pages (1984)).When methylation analysis to be applied to the analysis of bonding pattern of the glucose in glucan, first, make
All free hydroxymethylation in the glucose residue for forming glucan, next, the Portugal of hydrolysis exhaustive methylation gathers
Sugar.Next, the glucose that methylates hydrolyzed by also reason is and the glucitol that methylates as the different head dummy of cancellation, then
Person, free acetylating hydroxyl groups in the glucitol that makes to methylate at this and obtain partial methylation glucitol acetic acid esters (again
Person, sometimes by " partial methylation glucitol acetic acid esters " simply collectively referred to as " part methyl compound ").Pass through the part that will be obtained
Methide gas chromatographic analysis, is bonded style source in the various parts of each different glucose residues in glucan
The percentage (%) of the peak area for all parts methide that methide can be accounted in gas chromatogram with peak area represents.Into
And can be determined from this peak area % in the glucan bonding pattern different glucose residues there are ratio, i.e., each Portugal
Polyglycoside key there are ratio.Refer to the peak face in the gas chromatogram of methylation analysis relative to " ratio " of part methyl compound
Long-pending " ratio ", " the area % " in the gas chromatogram of methylation analysis is referred to relative to " % " of part methyl compound.
" glucose residue of α -1,4 keys " in above-mentioned (E) and (F) refers to only through the carbon atom bonding with 1 and 4
Hydroxyl and the glucose residue that is bonded with other glucose residues, in methylation analysis, as 2,3,6- trimethyls-Isosorbide-5-Nitrae,
5- triacetyl glucitols are detected.In addition, " α -1, the glucose residue of 6 keys " in above-mentioned (E) and (F) refer to only pass through with
The hydroxyl of the carbon atom bonding of 1 and 6 and the glucose residue being bonded with other glucose residues, in methylation analysis,
It is detected as 2,3,4- trimethyl -1,5,6- triacetyl glucitols.
The glucose residue and α -1 of the α obtained by methylation analysis-Isosorbide-5-Nitrae key, the ratio of the glucose residue of 6 keys and,
Relative to the glucose residue and α -1 of α-Isosorbide-5-Nitrae key, the ratio of the full glucose residue of the glucose residue of 6 keys can be by this branch
The structure of alpha-glucans mixture is overall as mixture, is used as one of index characterized by chemical method.
Above-mentioned (E) " ratio of the glucose residue of α -1,4 keys and the glucose residue of α -1,6 keys be in 1:0.6~1:4
Scope " regulation refer to this branch alpha-glucans mixture for methylation analysis when, the 2 of detection, 3,6- trimethyls-
The ratio of 1,4,5- triacetyls glucitol and 2,3,4- trimethyl -1,5,6- triacetyl glucitols is in 1:0.6~1:4 model
Enclose.In addition, above-mentioned (F) " glucose residue and α -1 of α-Isosorbide-5-Nitrae key, to account for full glucose residual by the glucose residue of 6 keys total
The regulation of more than the 55% of base " refers to this branch alpha-glucans mixture, in methylation analysis, 2,3,6- trimethyls-Isosorbide-5-Nitrae,
5- triacetyls glucitol and the total of 2,3,4- trimethyl -1,5,6- triacetyl glucitols account for partial methylation glucitol
More than the 55% of acetic acid esters.In general, starch is without only in the glucose residue of 1 and 6 bonding, and the glucose of α-Isosorbide-5-Nitrae key
Residue account for it is more than half in full glucose residue, so the important document of above-mentioned (E) and (F) mean that this branch alpha-glucans mixture has
From the complete different structure of starch.
Such as provided in the feature of above-mentioned (E) and (F), this branch alpha-glucans mixture, in a preferable embodiment
In, it is typically that certain degree has " α -1, the glucose residue of 6 keys " being not present in starch, but with high blood glucose value rise
Inhibition because have a more complicated branched structure can expect high blood glucose value rise inhibition, is removed as if necessary
α-Isosorbide-5-Nitrae key and α -1, outside 6 keys, preferably also α -1,3 keys and α -1,3,6 keys.Wherein, " α -1,3,6 keys " refer to " with 1,
3 positions of the hydroxyl of 3 and 6 are bonded (α -1,3,6 bondings) glucose residue with other glucose ".This branch alpha-glucans
Mixture, contains α -1,3 bondings and α -1,3,6 bondings are in bonding in order to there is more complicated branched structure with arbitrary ratio
Can, for example, α -1, the glucose residues of 3 bondings are preferably more than the 0.5% of full glucose residue less than 10%.It is in addition, well-behaved
Branch alpha-glucans mixture, α -1, the glucose residue of 3,6 bondings are preferably more than the 0.5% of full glucose residue.
It is above-mentioned " α -1,3 be bonded glucose residue be more than the 0.5% of full glucose residue can pass through less than 10% " by
When this branch alpha-glucans mixture is for methylation analysis, 2,4,6- trimethyls -1,3,5- triacetyl glucitols are with portion
More than the 0.5% of the glucitol acetic acid esters that methylates is divided to exist less than 10% and confirm.In addition, above-mentioned " α -1, the Portugal of 3,6 bondings
Grape saccharide residue is more than the 0.5% of full glucose residue " can by this branch alpha-glucans mixture, in methylation analysis,
Four acetyl glucitols of 2,4- dimethyl -1,3,5,6- are with more than 0.5% deficiency of partial methylation glucitol acetic acid esters
10% exists and confirms.
This branch alpha-glucans mixture also can by weight average molecular weight (Mw) and weight average molecular weight (Mw) divided by
Value (Mw/Mn) characterization of number average molecular weight (Mn).Weight average molecular weight (Mw) and number average molecular weight (Mn), for example, can
Obtained using size exclusion chromatography etc..In addition, calculate structure cost branch α-Portugal because of weight average molecular weight (Mw) can be based on
The average glucose degree of polymerization of branch's alpha-glucans of oligosaccharide mixture, this branch alpha-glucans mixture also can be by average grapes
Sugared degree of polymerization characterization.The average glucose degree of polymerization can subtract 18 from weight average molecular weight (Mw), divided by be used as glucose residue amount
162 and obtain.This branch alpha-glucans mixture that active ingredient as blood glucose value rise inhibitor uses, its average Portugal
Grape sugar polymerization is typically 8~500, be preferably 15~400, more preferably 20~300 be suitable.Furthermore branch's alpha-glucans
Mixture, the average glucose degree of polymerization is bigger, viscosity increase, the point that the average glucose degree of polymerization is smaller, viscosity more diminishes, shows
Show the property same with common glucan.Therefore, can according to the present invention blood glucose value rise inhibitor embodiment, suitably
Selection has this branch alpha-glucans mixture of the average glucose degree of polymerization for the viscosity for being suitable for requirement and uses.
As the Mw/Mn of weight average molecular weight (Mw) divided by the value of number average molecular weight (Mn), mean closer to 1
The deviation of the glucose polymerization degree of branched alpha-dextran molecule of the branch's alpha-glucans mixture formed is small.As blood glucose
This branch alpha-glucans mixture that the active ingredient of value rise inhibitor uses, although as long as Mw/Mn usually less than 20,
It can use without problems, but preferably less than 10, more preferably less than 5 be suitable.Furthermore requiring to provide specific Portugal
During branch's alpha-glucans mixture of the grape sugar degree of polymerization, for Mw/Mn close to 1, the deviation of glucose polymerization degree is smaller the more preferred.
As long as this branch alpha-glucans mixture has the feature of above-mentioned (A) or even (C), any method system just can be also used
Make.For example, make the non-reducing end grape of the straight-chain glucan of the oriented glucose polymerization degree more than 3 through α-Isosorbide-5-Nitrae key connection
Saccharide residue imports the enzyme effect of the effect of the branched structure of the glucose polymerization degree more than 1 connected through α -1,6 keys in starchiness
Obtained from branch's alpha-glucans mixture can suitably utilize in an embodiment of the present invention, as an example preferably, can lift
Phlorose based transferase disclosed in International Publication No. of sening as an envoy to WO2008/136331 separate editions acts on starchiness and obtains
Branch's alpha-glucans mixture.In addition, in addition to above-mentioned phlorose based transferase, since combination maltotetraose generation is formed sediment
The amylase of powder enzyme (EC3.2.1.60) etc., or the starch debranching enzymes of isoamylase (EC 3.2.1.68) etc., Ze Keshiben branches
Alpha-glucans mixture is degraded, molecular weight, glucose polymerization degree etc. can be adjusted to desired scope.Furthermore pass through connection
With cyclomaltodextrin glucanotransferase (CGTASE) (EC2.4.1.19), or Q-enzyrne (EC 2.4.1.18), in special open 2014-
Having disclosed in No. 054221 publication makes the α -1,4 glucans α -1,6 of the degree of polymerization more than 2 be transferred to the grape of amylaceous inside
The active enzyme of saccharide residue, can also make branch's alpha-glucans of structure cost branch alpha-glucans mixture further hyperbranched,
Improve the water-soluble dietary fiber content of this branch alpha-glucans mixture.Again make the saccharic hydrolase of glucoamylase etc.
For the branch's alpha-glucans mixture so obtained, gather as the branched alpha-Portugal for further improving water-soluble dietary fiber content
Sugared mixture is also random, by making glycosyl trehalose generate enzyme (EC 5.4.99.15) effect, is gathered to branched alpha-Portugal is formed
The reduction end of branch's alpha-glucans of sugared mixture imports trehalose structure, or also can reduce branch's alpha-glucans by hydrogen addition
Reduction end grade and reduce the reducing power of branch's alpha-glucans mixture, in addition, by carry out by size exclusion chromatography
Deng classification separation, it is also random that obtaining, which has branch's alpha-glucans mixture of desired molecular weight,.
As long as the amount of this branch alpha-glucans mixture in making to be contained in the blood glucose value rise inhibitor of the present invention with
Monosaccharide plays desired blood glucose value rise inhibitory action at the same time or when the front and rear intake of phase, is just not particularly limited, by this branch
Alpha-glucans mixture with 1~100 mass %, be preferably that 3~100 mass %, the more preferably scope of 5~100 mass % contain
Have.In addition, the blood glucose value rise inhibitor of the present invention, also can be according to need in addition to this branch alpha-glucans mixture
Will, by selected from water, mineral, the one kind or two or more component for spices, stabilization agent, excipient, extender, pH regulators etc.
With 0.01~50 mass %, it is preferably that the ratio of 0.1~40 mass % suitably coordinates and utilizes.
As long as the amount intake that the blood glucose value rise inhibitor of the present invention plays the action effect of blood glucose value rise inhibitor is
Can, intake is without particular limitation, for example, the intake of this branch alpha-glucans mixture as active ingredient, usually with
As adult (weight 60kg) every 1 time, the scope of 0.5~100g, be preferably the scope of 1~50g, more preferably 1.5~10g
Scope, further preferably be 3~8g scope mode, by the present invention blood glucose value raise inhibitor, directly, alternatively, be dissolved in water,
The beverage of tea, coffee etc. and absorb, or be added in Foods or drinks and absorb.Alternatively, active ingredient can also be used as
This branch alpha-glucans mixture intake relative to monosaccharide total intake as 0.5~30 mass % scope,
The mode of the more preferably scope of 5~15 mass % absorbs the blood glucose value rise inhibitor of the present invention.Furthermore certainly also can be by this
Blood glucose value rise inhibitor intake before and after the intake of Foods or drinks of invention.
The blood glucose value rise inhibitor of the present invention can be used as powdered, granular, graininess, liquid, paste, white shape, sheet,
Capsule shape, caplet shape, software capsule shape, lozenge shape, bar-shaped, tabular, bulk, pill shape, solid-like, gelatinous, glue, natural gum
The suitable form of shape, wafer-like, biscuit shape, maltosemalt sugar shape, masticatory pattern shape, syrupy shape, strip etc..In addition, the blood glucose value of the present invention
Rise inhibitor be not only medicine or quasi drug, can with specific health food, feature represent food, dietary supplement,
Or the food absorbed for the purpose of the habit disease that prevents or make the life better of healthy food etc. coordinates.Food as cooperation
Concrete example, can enumerate soda, milk beverage, fruit syrup, sports drink, vinegar beverage, soymilk, the beverage containing iron,
The food of the beverage of sour milk beverage, green tea, black tea, cocoa, coffee etc., rice, congee, bread, noodles, soup, sauce, yogurt etc.
Product, soft sweets, hard candy, natural gum, jelly, biscuit, soft biscuit, thin pancake, graupel cake, the candied cake of popped rice, asks fertilizer, cake class, fern cake, steamed stuffed bun, outer youth
Cake, filling class, red bean jelly, water red bean jelly, bright and beautiful jade, jelly, pectin jelly, the main chastity of family are good, biscuit, pretzel, group, pudding, cream, custard
Frost, cream foam dessert, Waffle, steamed sponge cake, pancake, muffin, doughnut, chocolate, Gan Na are permitted, cereal bar, mouth are fragrant
Dessert, ice cream, sherbet, the Gelato of sugar, caramel, nougat, flower cream, peanut cream, fruit cream, jam, marmalade etc.
Furthermore Deng the freezing point heart, soy sauce, sauce powder, sauce, powder sauce, fermented glutinour rice, eggplant cucumber sauce, seaweed salt, mayonnaise, baste,
Vinegar, three glasss of vinegar, powder sushi vinegar, the element of China, tempura dip, noodles flavoring are sauce, tomato sauce, catsup, roasting
The sauce of meat, the sauce of roast chicken, dry deep-frying powder, tempura powder, curried soup, stewed element, the element of soup, the element of meat soup, compound seasoner,
The various flavorings or conditioning processed goods of Japanese sweetener wine, new Japanese sweetener wine, table sugar, coffee candy etc..Furthermore blood of the invention
Sugared value raise inhibitor also can with the liquor for preventing or improving (treatment) lifestyle disease, syrup, through pipe nutrition
The medicament of the form of agent, lozenge, capsule, lozenge, sublingual dose, granule, powder, pulvis, emulsion, spray etc. coordinates.Again
Person, blood glucose value of the invention rise inhibitor can also coordinate with pet food or feed, the bait of the animal consumption beyond people.
In addition, the blood glucose value rise inhibitor of the invention containing this branch alpha-glucans mixture serves not only as direct blood
Sugar value rise inhibitor, in addition to the blood glucose value rise inhibitor of the present invention, can add monosaccharide again and be used as oral combination
Thing uses.The oral composition of the present invention containing blood glucose value due to raising inhibitor, due to containing monose in oral composition
Class, also can inhibit the rise of the blood glucose value after intake, even there is the elevated people of care about blood glucose value, can also not mind containing monose
The benefit absorbed to class.
For in passing, as the monosaccharide used in the oral composition of the present invention, can enumerate makes monose in people
Class intake after the elevated effect of blood glucose value monose, particularly, with food coordinate monose, for example, selected from glucose, fruit
Sugar, more than a kind of galactolipin, be exactly wherein, using as the different of the mixture of glucose, fructose and glucose and fructose
Structureization sugar, be particularly, when glucose is together coupled to the oral composition of the present invention with blood glucose value rise inhibitor, more appropriately
Play by the present invention blood glucose value rise inhibitor blood glucose value rise inhibition and it is preferred that.
In the oral composition of the present invention, the blood glucose value rise inhibitor of the present invention is raised using playing as blood glucose value
The amount of the action effect of inhibitor coordinates, use level is without particular limitation, for example, relative to containing in oral composition
The total amount of monosaccharide, this branch alpha-glucans mixture as active ingredient is preferably with the model for synthesizing 0.5~30 mass %
Enclose, be more preferably the scope of 5~15 mass %.Furthermore this branch alpha-glucans mixture as active ingredient can match somebody with somebody synthesis
To be grown up (weight 60kg) every 1 time, in general, the scope of 0.5~100g, be preferably 1~50g scope, more preferably 1.5~
The scope of 10g, further preferably for the scope of 3~8g, to absorb be suitable.
, can also be relative to the total amount of oral composition in addition to mentioned component in the oral composition of the present invention
And 0.01~50 mass %, it is preferably that the ratio of 0.1~40 mass % suitably coordinates selected from water, physiological saline, sweetening material, egg
White matter, peptide, polyphenol, mineral, antibacterial material, enzyme, the polysaccharide of indigestible, colouring matter, spices, thickener, stabilization agent, tax
Shape agent, extender, pH regulators etc. it is one kind or two or more.
The oral composition of the present invention can be used as powdered, granular, graininess, liquid, paste, white shape, sheet, capsule
Shape, caplet shape, software capsule shape, lozenge shape, bar-shaped, tabular, bulk, pill shape, solid-like, gelatinous, glue, gumminess,
The suitable form of wafer-like, biscuit shape, maltosemalt sugar shape, masticatory pattern shape, syrupy shape, strip etc..
The oral composition of the present invention also can be as needed, from the non-oral administration method applied through pipe etc. to stomach or digestion
Pipe is applied.
Hereinafter, the present invention is described in more detail based on experiment.
In following experiment 1, recorded using according to the embodiment 5 of International Publication No. WO2008/136331 separate editions
Method manufacture branch's alpha-glucans mixture.That is, the method recorded according to above-described embodiment 5, to 27.1 mass % corns
In addition liquefied starch (percent hydrolysis 3.6%) plus sodium hydrogensulfite add calcium chloride to becoming to 0.3 mass % of ultimate density is become
After ultimate density 1mM, 50 DEG C are cooled to, adds 11.1 units by International Publication No. WO2008/136331 per 1g solids to it
Bacillus circulans (Bacillus circulans) PP710 (FERM of method modulation described in the embodiment 1 of number separate edition
BP-10771) the concentration crude enzyme liquid of the phlorose based transferase in source, furthermore, 50 DEG C, pH6.0 effect 68 it is small when.Should
Reaction solution is after 80 DEG C are kept for 60 minutes, cooling, by the filtrate being obtained by filtration according to conventional methods, with activated carbon decolorizing, by H
Type and OH type ion exchange resin desalinations and purify, then concentrate, branch's alpha-glucans mixture for being spray-dried and manufacturing is following
Used in experiment 1.Furthermore by obtained branch's alpha-glucans mixture by International Publication No. WO2008/136331 separate editions
Paragraph 0079,0080 described in isomaltose glucanase digestion trial method, alpha-glucosidase and glucoamylase
When methylation assay described in digestion trial method, paragraph 0076~0078 is analyzed, there is the feature of following (a) or even (c).
(a) using glucose as being formed sugar,
(b) have through the key beyond α -1,4 keys and be connected to and be located at the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of straight-chain glucan,
(c) digested by isomaltose glucanase, the solids per digest generates 35 mass % isomaltoses.
In addition, when obtained branch's alpha-glucans mixture is analyzed by above-mentioned enzyme-HPLC methods, above-mentioned branch's alpha-glucans
Mixture, with the exception of the features described above, there is the feature of following (d), furthermore, from the analysis result by above-mentioned methylation assay,
Confirmation has the feature of following (e) or even (h).
(d) water-soluble dietary fiber content is 82.9 mass %,
(e) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is 1:2.1
(f) the total of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is full glucose residue
73.8%.
(g) glucose residue that α -1,3 is bonded is the 2.1% of full glucose residue.
(h) glucose residue that α -1,3,6 is bonded is the 5.6% of full glucose residue.
Furthermore the paragraph by branch's alpha-glucans mixture by International Publication No. WO2008/136331 separate editions
During the molecular weight distribution analysis of the gel filtration HPLC described in 0081, its weight average molecular weight (Mw) is 5,000 dalton
(be scaled the average glucose degree of polymerization then about 30), Mw/Mn are 2.1.
As described above, the branch's alpha-glucans mixture used in this experiment is using glucose as sugar is formed, have through
Key beyond α -1,4 keys and be connected to the straight-chain glucan of the glucose polymerization degree more than 3 connected through α -1,4 keys it is non-also
The branched structure of the glucose polymerization degree more than 1 of former terminal glucose saccharide residue, has different by isomaltose glucanase digestion generation
The feature of above-mentioned (A) or even (C) of maltose.In addition, the branch alpha-glucans mixture used in this experiment meet by
Isomaltose glucanase digests, and isomaltose is generated with below the 70 mass % of more than 5 mass % of every solids of digest
Feature, water-soluble dietary fiber content be more than 40 mass % above-mentioned (D) feature and, the glucose residue of α-Isosorbide-5-Nitrae key
1 is in the ratio of the glucose residue of α -1,6 keys:0.6~1:4 scope, the glucose residue and α -1 of α-Isosorbide-5-Nitrae key, 6 keys
Total more than 55% above-mentioned (E), feature of (F) for accounting for full glucose residue of glucose residue.
Furthermore above-mentioned branch's alpha-glucans mixture is α -1, the glucose residue of 3 bondings is in full glucose residue
More than 0.5% scope less than 10%, α -1, the glucose residue of 3,6 bondings are in more than the 0.5% of full glucose residue
Scope.
In following experiment, in order to study shadow of the branch's alpha-glucans mixture in glucose uptake to blood glucose value
Ring, implement glucose load experiment.
<Experiment 1:Glucose loading test>
To the blood glucose value on an empty stomach in addition to the person of the abnormal experience of the glucose metabolism energy for having diabetes etc. (before intake
Blood glucose value) be general 80~110mg/dL healthy 13 people of men and women subject to the control sample that will be only made of glucose
50g is dissolved in water (with reference to table 1) as the aqueous solution of 200mL, is absorbed within 5 minutes.Before intake, intake after 30,45,60,
90th, the meter of 120 minutes 6 times, take a blood sample from the finger tip of subject, use ph test paper ph " Accu-ChekAvivaStripF " (Roche
Diagnostics Co., Ltd. sells) and own blood glucose analyzer " Accu-ChekAvivaNano " (Roche
Diagnostics Co., Ltd. sells) and measure blood glucose value.Furthermore as glucose, use commercially available powder glucose (business
The name of an article " Fuji Crystar " plus the sale of rattan Chemical Co., Ltd.).
Next, from above-mentioned experiment after more than one week, for the subject of above-mentioned 13 people, taken the photograph with control sample
Situation about taking similarly absorb by with test specimens 55g (with reference to table 1) of the glucose together containing branch's alpha-glucans mixture
Water is dissolved in as the aqueous solution of 200mL, after intake, is similarly taken a blood sample, the change to blood glucose value is measured.
【Table 1】
* glucose and branch's alpha-glucans mixture are dissolved in water, 200mL is used as using full dose.
For above-mentioned 13 people of subject control sample absorb when and test specimens absorb when, be each made relative to intake
Afterwards before elapsed time plotting intake, 30 after intake, the coordinate of the average value of the increment of the blood glucose value of 45,60,90,120 minutes
Figure, is shown in Fig. 1.In addition, calculating the area under the curve (AUC) of the average value of the increment of blood glucose value per sample, table 2 is shown in.Furthermore
AUC when AUC divided by control sample when the influence of branch alpha-glucans mixture intake is absorbed by test specimens are absorbed and obtain
The AUC ratios evaluation arrived, as a result in table 2 and remembers.
【Table 2】
*:(test specimens AUC/ control sample AUC) × 100
As shown in Figure 1, (symbol zero of Fig. 1) compares when being absorbed with control sample, (the symbol of Fig. 1 when test specimens absorb
●) rise of the increment of blood glucose value is suppressed.In addition, as shown in table 2, AUC when control sample absorbs is 99.0, with this phase
Right, AUC when test specimens absorb down to 86.6, AUC ratios is 87.4%.Confirmed from result, branch's alpha-glucans mixing
If thing is together absorbed with the glucose as monose, with only absorbing glucose when ratio, significantly suppress the rise of blood glucose value.
For in passing, this branch alpha-glucans mixture with Starch Fraction decomposition product (maltodextrin) when together absorbing
Suppress the rise of blood glucose value in the International Publication No. WO2008/136331 separate editions by the applicant identical with the applicant
It is open.Above-mentioned experimental result represents, branch's alpha-glucans mixture, when being not only intake Starch Fraction decomposition product, even in taking the photograph
Take the rise for also suppressing blood glucose value during monosaccharide.
On the one hand, as previously mentioned, in the art as the widely used indigestibility of water-soluble dietary fiber raw material
Property dextrin, the rise for reporting the blood glucose value after the intake for glucose and fructose as monose do not show inhibition
(with reference to non-patent literature 3 and 4).This branch alpha-glucans mixture and indigestible dextrins, although being the grape that has branch
The polymer of sugar, is that the point of the mixture for the starch source for having water-soluble dietary fiber is common, after glucose uptake
The elevated influence of blood glucose value is not both the opinion for the extremely interest depth for overturning conventional common technical knowledge, this branch alpha-glucans mixes
Compound, the point of the extraction of the glucose in organism is at least significantly suppressed, it is believed that its action effect and indigestible dextrins
There is notable difference.
This branch alpha-glucans mixture is due to playing the rise suppressed as the blood glucose value after the glucose uptake of monose
Action effect, even worrying to cause the rise of blood glucose value all the time, the food containing monosaccharide, for example, containing grape
Various foods of the monosaccharide of sugar, fructose, isomerized sugar etc. as sweetening material, as long as this branch alpha-glucans mixture is matched somebody with somebody
Close, can expect to can inhibit the rise of the blood glucose value after absorbing.If using this branch alpha-glucans mixture, can expand can be without blood
The scope of the food absorbed to the elevated mystery of sugared value, this branch alpha-glucans mixture, inhibitor is raised as blood glucose value,
It is more favourable than very widely used today indigestible dextrins in the field of food containing monosaccharide, especially field of beverage
Ground utilizes.
In following experiment 2, press down as the blood glucose value after the bright monose by this branch alpha-glucans mixture absorbs is solved
One means of the mechanism of making, by influence of this branch alpha-glucans mixture to the glucose absorption in small intestine by using big
Mouse invert small intestine verification experimental verification, and with the results contrast of the indigestible dextrins on progress.
<Experiment 2:The mechanism of blood glucose value rise inhibitory action after being absorbed by the monosaccharide of branch's alpha-glucans mixture-
Using rat reversion small intestine experiment->
In order to verify the mechanism of the blood glucose value of this branch alpha-glucans mixture in people rise inhibitory action, using big
Mouse inverts small intestine and inquires into the influence to the glucose absorption in small intestine.As this branch alpha-glucans mixture, using with
The identical standard items used in experiment 1, as indigestible dextrins, use commercially available indigestible dextrins (trade name
" Fibersol2 ", SongGu Chemical Industrial Co., Ltd sell).
For in passing, (it see, for example, positive man of virtue and ability of earth house etc., the Portugal on rat reversion small intestine using the experiment of reversion small intestine
The research that grape sugar absorbs:Through when observation exploitation Japan digester disease association magazine, volume 80,1138-1143 pages (1983
Year)) refer to study for the transmission mechanism of the specific part to enteron aisle, extract its part and invert, ligation both ends, be allowed to
The method that the transmission of material is inquired into as cryptomere, such as buffer solution is put among capsule, while containing object material (this
Glucose in experiment) experimental liquid in lead to 95%O2- 5%CO2Gas, while being incubated to capsule.To in the experimental liquid
Object material is absorbed from mucous membrane of small intestine, is migrated to the amount of the serosa side of intracapsular side and is measured, and evaluation absorbs.Invert enteron aisle and
Make mucous membrane lateral outer, since epithelial cell requires substantial amounts of oxygen, make its supply easily by as the first reason.In this experiment
In, in vitro through when measure by small intestine glucose absorption.
<Test 2-1:Rat inverts the modulation of small intestine>
Wistar rats (hero, 7 week old, the sale of CLEA Co., Ltd. of Japan) are bought, were raised at 1~3 week to standard feed
Educate and tame.Next, make the rat go on a hunger strike 4 it is small when after, by under anaesthetized with pentobarbital midsection opening abdomen and
Small intestine is gathered, (stage casing of small intestine is in the Treitz ligaments of the rat small intestine than collection, small intestine is tied to the wall of side in the back of the body
The structure of the ligament sample of (posterior abdominal wall)) lower side (ileum side) cut out about 16cm to 24cm position length about 8cm part
Small intestine, uses in test.
<Test 2-2:Tested using the glucose absorption of reversion small intestine>
Glucose absorption experiment using rat reversion small intestine is the experimental rig shown in Fig. 2 to be made, according to following
Order is implemented.
<Experimental rig>
Hereinafter, for the summary of experimental rig, illustrated based on Fig. 2.Injection tube (the symbol d) of Fig. 2 is held with plastics 20mL
Used as container, gas exhaust aperture is set on the top of injection tube d, and (the symbol b) of Fig. 2, is installed in the lower end of injection tube d
Gas backstreaming pipe (the symbol h) of Fig. 2.In rubber bolt (the central portion perforate of the symbol a) of Fig. 2, the plastics of insertion cut-out tip
1mL chips processed (the symbol c) of Fig. 2, in the tip of the chip c, the reversion small intestine of installation ligation one end (the symbol e) of Fig. 2 and
Ligation.It is inserted into from the upper end of injection tube d, as experimental rig.
<Test sequence>
(1) will only glucose, glucose and branch's alpha-glucans mixture or, glucose and indigestible dextrins are each
From Krebs-Ringer bicarbonate buffers (pH7.4) (hreinafter referred to as " KRB buffer solutions ") are dissolved in, following 3 kinds are modulated
Given the test agent solution.
Control group:Only glucose (180mg/dL, 10mM);
Branch's alpha-glucans mixture addition group:To the alpha-glucans mixing of glucose (180mg/dL, 10mM) addition branch
Thing (60mg/dL);
Indigestible dextrins addition group:To glucose (180mg/dL, 10mM) addition indigestible dextrins (60mg/dL);
(2) injection tube (symbol d) injection 20mL (the above-mentioned 3 kinds of test samples of symbol g) of Fig. 2 of Fig. 2 are held to plastics 20mL
Any one of product solution, is put into 37 DEG C of Water Tank with Temp.-controlled and (the symbol h) of Fig. 2, is passed through 95%O from gas backstreaming pipe2- 5%
CO2Gas, carries out gas backstreaming.
(3) by the inside of the rat small intestine obtained in 2-1 is tested with being passed through 95%O2- 5%CO2The cold KRB bufferings of gas
Liquid cleans.
(4) reversion rod (not shown) is inserted into a little to the peri position end of enteron aisle, while it is pressed into reversion rod to small enteral, one
Side inverts, as reversion small intestine.
(5) by the way that to the reversion small intestine taken off from reversion with rod, (the plastics 1mL of tip is cut off in the symbol e) insertions of Fig. 2
Chip (symbol c)-ligation of Fig. 2 and install, ligature from peri position end about at 5cm.
(6) the chip c for installing reversion small intestine e is arranged on to the inside of injection tube d, with micropipettor from the upper of chip c
KRB buffer solutions 0.5mL (the symbol f) of Fig. 2 inject to reversion tunica serosa intestini tenuis side (inner side of reversion small intestine c) in portion.Make in this time point
Start for experiment (incubation).Furthermore before experiment and in experiment, by 95%O2- 5%CO2Gas is passed through mucous membrane side (reversion small intestine c
Outside) given the test agent solution g.
(7) mucous membrane side, serosa side are incubating the time point of 0,30,60,90,120 minute by the micro shiftings of each 5 μ L of solution
Liquid device samples, and uses glucose quantitation kit (trade name " glucose CII tests WAKO ", Wako Pure Chemical Industries, Ltd.
Sale) and quantifying glucose.
(8) each test sample group is each tested 6 times, and the inspection of data, is compared with Tukey-Kramer methods.With danger
Dangerous rate is used as " there were significant differences " less than 0.05.
Using reversion small intestine glucose absorption experiment in, through when measure serosa side concentration of glucose the results are shown in
Table 3.
【Table 3】
*:Average value ± standard deviation, n=6, in different intersymbols there were significant differences (p<0.05)
As shown in table 3, learn in control group (only glucose), the concentration of glucose of serosa side divides in on-test 30
Clock, 60 minutes, 90 minutes, the time point of 120 minutes, each up to 31.5 ± 10.9mg/dL, 96.2 ± 17.8mg/dL, 155.2
± 23.0mg/dL, 202.8 ± 27.5mg/dL, concentration of glucose rise with time going by, inverts intestinal absorption mucous membrane
The glucose of side, moves to serosa side.On the one hand, in branch's alpha-glucans mixture addition group, the glucose of serosa side is dense
Degree at the time point of 30 minutes on-tests, 60 minutes, 90 minutes, 120 minutes, be respectively 13.3 ± 6.6mg/dL, 40.4 ±
26.5mg/dL, 71.7 ± 40.6mg/dL, 102.7 ± 58.3mg/dL are significantly lower compared to the control group in each time showing
Value.In addition, indigestible dextrins addition group is shown and result of the control group without big difference.Result more than learns, branched alpha-Portugal
Oligosaccharide mixture plays the role of suppressing the glucose absorption in mucous membrane of small intestine, and on the other hand, indigestible dextrins press down without absorption
Make and use.
Further, since the enteral amount of buffer of reversion after incubating 120 minutes often tests not necessarily certain, experiment knot
Serosa side amount of buffer during beam is multiplied by concentration of glucose and calculates the full glucose amount of reversion tunica serosa intestini tenuis side.Control group, divide
Branch alpha-glucans mixture addition group and, the enteral full glucose amount of the reversion of indigestible dextrins addition group is individually
1.15 ± 0.27mg, 0.47 ± 0.34mg and, 0.93 ± 0.33mg, in the same manner as the situation of the concentration of glucose shown in table 3,
It is significantly fewer than the glucose amount of absorption with control group in branch's alpha-glucans mixture addition group.On the one hand, in absorption
In full glucose amount, indigestible dextrins addition group and control group are also without big difference.
As understood from the above, branch's alpha-glucans mixture addition group is with compareing (only glucose) group and indigestible
Dextrin addition group ratio, the uptake of glucose is significantly few when 90~120 minutes after sugar loads.On the one hand, indigestible is pasted
Smart addition group is with control group without big difference.Result more than judges that branch's alpha-glucans mixture has the grape in small intestine
The absorption inhibitory action of sugar, on the one hand, absorption inhibitory action of the indigestible dextrins without glucose.For in passing, indigestible
Dextrin does not show in the glucose absorption experiment using reversion small intestine absorbs inhibitory action in document (if woods is luxuriant, " indigestible is pasted
Influence of the essence to sugar tolerance ", day endocrine can will, volume 68,623-635 pages (1992)) in also have report.
From the result confirmation of experiment 2, this branch alpha-glucans mixture suppresses the extraction of the glucose in small intestine.Therefore
Confirm, the blood glucose value rise in the glucose uptake of the people by this branch alpha-glucans mixture suppresses to be by small intestine
The absorption of glucose suppresses.Learnt by this experiment, monosaccharide of the indigestible dextrins in organism does not show blood glucose when absorbing
Value rise inhibitory action, on the other hand, this branch alpha-glucans mixture show the one of blood glucose value rise inhibitory action because being pair
The difference of the effect of glucose absorption in small intestine.
How this branch alpha-glucans mixture acts on and to suppress extraction of the glucose in small intestine to blood unknown, but
Have through the key connection beyond α-Isosorbide-5-Nitrae key to this branch alpha-glucans mixture, the glucose polymerization degree connected through α-Isosorbide-5-Nitrae key
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of more than 3 straight-chain glucan, has by different
The feature of the structure of maltose dextranase digestion generation isomaltose, is more preferably digested by isomaltose glucanase, had
The feature of the structure of the solids generation 70 following isomaltoses of mass % of more than 5 mass % per digest is estimated to be for hair
Wave function necessity.
Furthermore due to branched alpha of the isomaltose growing amount in being digested in isomaltose glucanase less than 5 mass %-
Glucan mixture is close to the structure of the few maltodextrin of branched structure, is estimated to be for the glucose in small intestine
Extraction influence it is small.On the one hand, the isomaltose growing amount in isomaltose glucanase digestion surpasses point of 70 mass %
Branch alpha-glucans mixture becomes close to as with α -1, the structure of the glucan of the glucose polymer of 6 key connections, on the contrary,
Since branched structure becomes dull on the contrary, the influence for being estimated to be the extraction to the glucose in small intestine diminishes.In addition, by this
The water-soluble dietary fiber content that high-performance liquid chromatograph method (enzyme-HPLC methods) is obtained among branch's alpha-glucans mixture is 40
More than quality % due to itself in small intestine indigestibility absorb and be estimated to be more preferably.
On the one hand, indigestible dextrins do not suppress the extraction of the glucose in small intestine.Although indigestible dextrins for
Inhibition is shown in the rise of the blood glucose values after saccharic intake more than disaccharides, as the blood glucose value after being absorbed for monosaccharide
Rise does not show the mechanism of action of inhibition, is estimated to be since indigestible dextrins suppress what is interlocked with disaccharides catabolic enzyme
The extraction of glucose.
Hereinafter, the present invention is described in more detail based on embodiment.But the present invention limits from these embodiments.
【Embodiment】
【Embodiment 1】
<Blood glucose value raises inhibitor>
According to the method described in the embodiment 5 of International Publication No. WO2008/136331 separate editions, branched alpha-Portugal is modulated
Oligosaccharide mixture powder.Furthermore obtained branch's alpha-glucans mix powder has the feature of following (a) or even (g).
(a) using glucose as being formed sugar,
(b) have through the key connection beyond α -1,4 keys to positioned at the straight of the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of chain glucan,
(c) digested by isomaltose glucanase, isomaltose generated with the 35 mass % of every solids of digest,
(d) water-soluble dietary fiber content is 80.8 mass %,
(e) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is 1:2.2
(f) the total of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is full glucose residue
72.9%,
(g) the average glucose degree of polymerization is that 31, Mw/Mn is 2.0.
The active ingredient that this product can raise inhibitor as blood glucose value utilizes.In addition, by absorbing this product, it can suppress people's
The rise of blood glucose value after monosaccharide intake.This product is usually to be grown up (weight 60kg) every 1 time, the scope of about 0.5~about 100g,
This product is direct, alternatively, being dissolved in the beverage of water, tea, coffee etc. and absorbing, or it is added in Foods or drinks and absorbs i.e.
Can.Certainly also can be by this product intake before and after the intake of Foods or drinks.This product itself is tasteless, no foreign odor, in room
Also non-hygroscopic under temperature, discoloration, stablized through more than 1 year.
【Embodiment 2】
<Blood glucose value raises inhibitor>
According to the method described in the experiment 2-2 of International Publication No. WO2008/136331 separate editions, solid constituent is modulated
Branch's alpha-glucans mixture solution of 30 mass % of concentration, thereafter, is spray-dried and obtains branched alpha-Portugal according to conventional methods
Oligosaccharide mixture powder.Furthermore obtained branch's alpha-glucans mix powder has the feature of following (a) or even (g).
(a) using glucose as being formed sugar,
(b) have through the key connection beyond α -1,4 keys to positioned at the straight of the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of chain glucan,
(c) digested by isomaltose glucanase, isomaltose generated with the 27.2 mass % of every solids of digest,
(d) water-soluble dietary fiber content is 41.8 mass %,
(e) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is 1:0.6,
(f) the total of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is full glucose residue
83.0%,
(g) the average glucose degree of polymerization is that 405, Mw/Mn is 16.2.
The active ingredient that this product can raise inhibitor as blood glucose value utilizes.In addition, by absorbing this product, it can suppress people's
The rise of blood glucose value after monosaccharide intake.This product is usually to be grown up (weight 60kg) every 1 time, the scope of about 0.5~about 100g,
This product is direct, alternatively, being dissolved in the beverage of water, tea, coffee etc. and absorbing, or it is added in Foods or drinks and absorbs i.e.
Can.Certainly also can be by this product intake before and after the intake of Foods or drinks.This product itself is tasteless, no foreign odor, in room
Also non-hygroscopic under temperature, discoloration, stablized through more than 1 year.
【Embodiment 3】
<Blood glucose value raises inhibitor>
According to the method described in the embodiment 6 of International Publication No. WO2008/136331 separate editions, branched alpha-Portugal is modulated
Oligosaccharide mixture powder.Furthermore obtained branch's alpha-glucans mix powder has the feature of (a) or even (g).
(a) using glucose as being formed sugar,
(b) have through the key connection beyond α -1,4 keys to positioned at the straight of the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of chain glucan,
(c) digested by isomaltose glucanase, isomaltose generated with the 40.6 mass % of every solids of digest,
(d) water-soluble dietary fiber content is 77.0 mass %,
(e) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is 1:4,
(f) the total of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is full glucose residue
67.9%,
(g) the average glucose degree of polymerization is that 18, Mw/Mn is 2.0.
The active ingredient that this product can raise inhibitor as blood glucose value utilizes.In addition, by absorbing this product, it can suppress people's
The rise of blood glucose value after monosaccharide intake.This product is usually to be grown up (weight 60kg) every 1 time, the scope of about 0.5~about 100g,
This product is direct, alternatively, being dissolved in the beverage of water, tea, coffee etc. and absorbing, or it is added in Foods or drinks and absorbs i.e.
Can.Certainly also can be by this product intake before and after the intake of Foods or drinks.This product itself is tasteless, no foreign odor, in room
Also non-hygroscopic under temperature, discoloration, stablized through more than 1 year.
【Embodiment 4】
<Blood glucose value raises inhibitor>
In addition to 2 unit maltotetraoses generation amylase is added per 1g solids again to cornstarch liquefier, root
According to the method described in the embodiment 5 of International Publication No. WO2008/136331 separate editions, modulation branch alpha-glucans mixture
Powder.Furthermore obtained branch's alpha-glucans mix powder has the feature of (a) or even (g).
(a) using glucose as being formed sugar,
(b) have through the key connection beyond α -1,4 keys to positioned at the straight of the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of chain glucan,
(c) digested by isomaltose glucanase, isomaltose generated with the 41.9 mass % of every solids of digest,
(d) water-soluble dietary fiber content is 69.1 mass %,
(e) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is 1:2.4
(f) the total of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is full glucose residue
64.2%,
(g) the average glucose degree of polymerization is that 13, Mw/Mn is 2.0.
The active ingredient that this product can raise inhibitor as blood glucose value utilizes.In addition, by absorbing this product, it can suppress people's
The rise of blood glucose value after monosaccharide intake.This product is usually to be grown up (weight 60kg) every 1 time, the scope of about 0.5~about 100g,
This product is direct, alternatively, being dissolved in the beverage of water, tea, coffee etc. and absorbing, or it is added in Foods or drinks and absorbs i.e.
Can.Certainly also can be by this product intake before and after the intake of Foods or drinks.This product itself is tasteless, no foreign odor, in room
Also non-hygroscopic under temperature, discoloration, stablized through more than 1 year.
【Embodiment 5】
<Blood glucose value raises inhibitor>
Make amyloglucosidase (glucoamylase) act on the branched alpha that is obtained with the method described in embodiment 1-
Glucan mixture, undecomposed component is taken using gel permeation chromatography point.Thereafter, purify and be spray-dried according to conventional methods
And modulate branch's alpha-glucans mix powder.Furthermore obtained branch's alpha-glucans mixture has the feature of (a) or even (g).
(a) using glucose as being formed sugar,
(b) have through the key connection beyond α -1,4 keys to positioned at the straight of the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of chain glucan,
(c) digested by isomaltose glucanase, isomaltose generated with the 21 mass % of every solids of digest,
(d) water-soluble dietary fiber content is 94.4 mass %,
(e) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is 1:1.9
(f) the total of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is full glucose residue
64%,
(g) glucose polymerization degree is that 22, Mw/Mn is 1.7.
The active ingredient that this product can raise inhibitor as blood glucose value utilizes.In addition, by absorbing this product, it can suppress people's
The rise of blood glucose value after monosaccharide intake.This product is usually to be grown up (weight 60kg) every 1 time, the scope of about 0.5~about 100g,
This product is direct, alternatively, being dissolved in the beverage of water, tea, coffee etc. and absorbing, or it is added in Foods or drinks and absorbs i.e.
Can.Certainly also can be by this product intake before and after the intake of Foods or drinks.This product itself is tasteless, no foreign odor, in room
Also non-hygroscopic under temperature, discoloration, stablized through more than 1 year.
【Embodiment 6】
<Oral composition (powder juice)>
For 33 mass parts of orange fruit juice powder by spray drying manufacture, by what is obtained with the method described in embodiment 5
10 mass parts of branch's alpha-glucans mix powder, 20 mass parts of glucose, 20 mass parts of anhydrous crystalline maltitol, anhydrous lemon
0.65 mass parts of lemon acid, 0.1 mass parts of malic acid, 2-O- be alpha-glucose-based -0.2 mass parts of L-AA, citric acid soda
The appropriate good mixing of 0.1 mass parts and powder perfume, crushing form micropowder, it are fed intake to fluidized bed pelletizer,
As 40 DEG C of temperature of outgoing air, the branch's alpha-glucans powder that will be obtained with the method for embodiment 1 of spraying in right amount as adhesive
End is dissolved in solution obtained from water, is granulated within 30 minutes, metering, packs and obtain product.This product is to contain fruit juice containing monosaccharide
The powder juice for having rate about 30%.This product is due to coordinate branch's alpha-glucans as the blood glucose value rise inhibitor containing monosaccharide
Mixture, the elevated powder juice of blood glucose value when can inhibit intake.In addition, this product is free from extraneous odour, foreign odor, as juice commodity valency
Value is high.
【Embodiment 7】
<Oral composition (custard frost)>
By 100 mass parts of cornstarch, the branch's alpha-glucans mix powder obtained with the method described in embodiment 4
30 mass parts, 70 mass parts of water crystallization containing trehalose, 40 mass parts of glucose and 1 mass parts of salt are sufficiently mixed, and add chicken
280 mass parts of egg and stir, slowly add the cow's milk 1 of boiling to it, 000 mass parts, then the roasting lasting stirring of fire, in cornstarch
Fully be gelatinized and it is overall become translucent when only fire, it is cooled down, adds suitable chinese cymbidium spices, metering, filling, bag
Fill and obtain product.This product is that the custard containing monosaccharide, disaccharides, polysaccharide is white.This product is due to as containing monosaccharide, two
Carbohydrate, the blood glucose value rise inhibitor of polysaccharide coordinate branch alpha-glucans mixture, the liter of blood glucose value when can inhibit intake
High custard frost.In addition, this product is that have smooth gloss, the custard frost of excellent flavor and high-quality.
【Embodiment 8】
<Oral composition (dietary supplement)>
With glucose 247g, the branch alpha-glucans mix powder 217g obtained used in the method described in embodiment 3,
Mixture 15g, ascorbic acid before ferric pyrophosphate suspension (sun Chemical Corporation trade name SunActiveFeM) 8g, vitamin
Sodium 3g, Zn-contained yeast 0.5g, chromium yeast 0.3g, sucralose 0.2g put into prilling granulator as former end is granulated.On the one hand, exist
It is granulated adjustment dissolving coffee extract powder 15g, magnesium sulfate 10g in water 100mL.Make when granulation original is last to be mixed in the device from spray
Little by little mist projection granulating adjusts liquid and granulates for the tip of mouth, and nitrogen is filled into aluminium bag to as 1 packaging 5.15g or 1 packaging
10.3g.This product is the dietary supplement containing monosaccharide.This product is due to match somebody with somebody as the blood glucose value rise inhibitor containing monosaccharide
Branch alpha-glucans mixture is closed, the elevated dietary supplement of blood glucose value when can inhibit intake.In addition, this product is to be no different
Taste, foreign odor are high as dietary supplement commodity value.
【Embodiment 9】
<Oral composition (black tea drinks)>
Manufacture using the branch's alpha-glucans mix powder obtained used in the method described in embodiment 1 and be used as this hair
The black tea of bright oral composition.Relative to tealeaves 15g plus boiled water 1L, filtering tea and obtain black tea extracting solution 1L.With
Add 60g isomerized sugars again to 1L black tea extracting solutions with the black tea of the addition of weight ratio 2%, 3%, 4% branch alpha-glucans mixture
As respective black tea drinks A, B, C of the invention.In addition, in addition to being not added with the point of branch's alpha-glucans mixture, to use
The black tea drinks that method similar to the above obtains are as control.When carrying out sensory evaluation by 20~men and women 10 over fifty years old,
Learn the effect for covering the distinctive bitter taste of polyphenol contained in black tea drinks or astringent taste.Furthermore learn, black tea of the invention
Even if beverage A, B, C are stored at room temperature, also with compare and bloom phenomenon (by the phenomenon of black tea slowly cold then gonorrhoea)
It is suppressed.
This product is the black tea drinks containing monosaccharide.This product is due to coordinate as the blood glucose value rise inhibitor containing monosaccharide
The elevated black tea drinks of branch's alpha-glucans mixture and blood glucose value when can inhibit intake.In addition, this product be free from extraneous odour, it is different
It is smelly, it is high as black tea drinks commodity value.【Industrial applicibility】
It is as described above, suppression is raised by the blood glucose value of the invention using this branch alpha-glucans mixture as active ingredient
Preparation, since itself low sweet taste of this branch alpha-glucans mixture as active ingredient is to tasteless, can obtain utilization scope
The elevated benefit of blood glucose value that is wide, being not limited to after " people of diabetes borderline region " suppression monosaccharide intake.It is in addition, of the invention
Oral composition due to monosaccharide together containing the present invention blood glucose value raise inhibitor, have also unnecessary even if being absorbed
The elevated benefit of care about blood glucose value.The present invention makes this area huge contribution, meaningful invention really.
【The explanation of symbol】
In Fig. 1,
○:The average value (Δ blood glucose) of the increment of blood glucose value during the control sample that intake is only made of glucose
●:Intake and the increment of blood glucose value during test specimens of the glucose together containing branch's alpha-glucans mixture
Average value (Δ blood glucose)
In fig. 2,
a:Rubber bolt
b:Exhaust aperture
c:Cut off the plastics 1mL chips of tip
d:Plastics 20mL holds injection tube
e:Invert small intestine
f:Serosa side buffer solution
g:Mucous membrane side buffer solution
h:95%O2- 5%CO2Gas backstreaming is managed
Claims (7)
1. suppress people monosaccharide intake after blood glucose value elevated blood glucose value rise inhibitor, its with have following (A) or even
(C) branch's alpha-glucans mixture of feature is as active ingredient:
(A) using glucose as being formed sugar,
(B) have through the key connection beyond α -1,4 keys to the straight-chain positioned at the glucose polymerization degree more than 3 through α -1,4 key connections
The branched structure of the glucose polymerization degree more than 1 of the non-reducing end glucose residue of one end of glucan,
(C) generation isomaltose is digested by isomaltose glucanase.
2. the blood glucose value rise inhibitor described in claim 1, it is characterised in that above-mentioned branch's alpha-glucans mixture is by different
Maltose dextranase digests, and isomaltose is generated with below the 70 mass % of more than 5 mass % of every solids of digest
Branch's alpha-glucans mixture.
3. described in claim 1 or 2 blood glucose value rise inhibitor, wherein above-mentioned branch's alpha-glucans mixture be have it is following
(D) branch's alpha-glucans mixture of feature:
(D) the water-soluble dietary fiber content obtained by high-performance liquid chromatograph method (enzyme-HPLC methods) is more than 40 mass %.
4. any one of them blood glucose value rise inhibitor of claims 1 to 3, wherein above-mentioned branch's alpha-glucans mixture is
There is branch's alpha-glucans mixture of the feature of following (E) and (F):
(E) ratio of the glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys is in 1:0.6~1:4 scope;And
(F) glucose residue of the glucose residue of α -1,4 keys and α -1,6 keys it is total account for the 55% of full glucose residue with
On.
5. any one of them blood glucose value rise inhibitor of Claims 1 to 4, it is characterised in that above-mentioned branch's alpha-glucans
The average glucose degree of polymerization of mixture is 8~500.
6. oral composition, it is characterised in that containing Claims 1 to 5 any one of them blood glucose value rise inhibitor and
Monosaccharide.
7. the oral composition described in claim 6, it is characterised in that monosaccharide is at least one kind of selected from glucose and fructose.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202211163549.3A CN115475177A (en) | 2015-09-18 | 2016-09-15 | Blood sugar level increase inhibitor and oral composition containing the same |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015186047 | 2015-09-18 | ||
JP2015-186047 | 2015-09-18 | ||
JP2016-120685 | 2016-06-17 | ||
JP2016120685 | 2016-06-17 | ||
PCT/JP2016/077303 WO2017047706A1 (en) | 2015-09-18 | 2016-09-15 | Inhibitor for blood glucose level increase and oral composition comprising same |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211163549.3A Division CN115475177A (en) | 2015-09-18 | 2016-09-15 | Blood sugar level increase inhibitor and oral composition containing the same |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108025019A true CN108025019A (en) | 2018-05-11 |
Family
ID=58289366
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201680053826.1A Pending CN108025019A (en) | 2015-09-18 | 2016-09-15 | Blood glucose value raises inhibitor and the oral composition containing it |
CN202211163549.3A Pending CN115475177A (en) | 2015-09-18 | 2016-09-15 | Blood sugar level increase inhibitor and oral composition containing the same |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202211163549.3A Pending CN115475177A (en) | 2015-09-18 | 2016-09-15 | Blood sugar level increase inhibitor and oral composition containing the same |
Country Status (4)
Country | Link |
---|---|
JP (1) | JP7217089B2 (en) |
KR (1) | KR20180053361A (en) |
CN (2) | CN108025019A (en) |
WO (1) | WO2017047706A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP7045804B2 (en) * | 2017-05-16 | 2022-04-01 | サントリーホールディングス株式会社 | Beverages containing water-soluble dietary fiber |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008248133A (en) * | 2007-03-30 | 2008-10-16 | Nippon Meat Packers Inc | Beta-glucan material of eisenia bicyclis origin |
WO2008136331A1 (en) * | 2007-04-26 | 2008-11-13 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | BRANCHED α-GLUCAN, α-GLUCOSYLTRANSFERASE PRODUCING THE SAME, METHOD FOR PRODUCING THE SAME AND USE THEREOF |
JP2009263655A (en) * | 2008-03-31 | 2009-11-12 | Adeka Corp | beta-GLUCAN COMPOSITION |
US20100010710A1 (en) * | 2006-04-13 | 2010-01-14 | Daimlerchrysler Ag | System for Influencing the Driving Behavior of a Vehicle |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0723315B2 (en) * | 1986-02-28 | 1995-03-15 | 日本食品化工株式会社 | Blood sugar elevation inhibitor |
JP2643669B2 (en) * | 1990-12-28 | 1997-08-20 | 共成製薬株式会社 | Algin-containing foods |
JPH0769910A (en) * | 1993-09-01 | 1995-03-14 | Otsuka Pharmaceut Co Ltd | Composition for improving lipid metabolism and suppressing increase of blood sugar level |
JPH08131096A (en) * | 1994-11-15 | 1996-05-28 | Maruhei:Kk | Production of konjak |
-
2016
- 2016-09-15 KR KR1020187010441A patent/KR20180053361A/en not_active Application Discontinuation
- 2016-09-15 CN CN201680053826.1A patent/CN108025019A/en active Pending
- 2016-09-15 WO PCT/JP2016/077303 patent/WO2017047706A1/en active Application Filing
- 2016-09-15 CN CN202211163549.3A patent/CN115475177A/en active Pending
- 2016-09-15 JP JP2017539974A patent/JP7217089B2/en active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20100010710A1 (en) * | 2006-04-13 | 2010-01-14 | Daimlerchrysler Ag | System for Influencing the Driving Behavior of a Vehicle |
JP2008248133A (en) * | 2007-03-30 | 2008-10-16 | Nippon Meat Packers Inc | Beta-glucan material of eisenia bicyclis origin |
WO2008136331A1 (en) * | 2007-04-26 | 2008-11-13 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | BRANCHED α-GLUCAN, α-GLUCOSYLTRANSFERASE PRODUCING THE SAME, METHOD FOR PRODUCING THE SAME AND USE THEREOF |
EP2151500A1 (en) * | 2007-04-26 | 2010-02-10 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Branched -glucan, -glucosyltransferase producing the same, method for producing the same and use thereof |
CN103865967A (en) * | 2007-04-26 | 2014-06-18 | 株式会社林原 | Branched alpha-glucan, alpha-glucosyltransferase for producing the same, manufacturing method and use therefor |
JP2009263655A (en) * | 2008-03-31 | 2009-11-12 | Adeka Corp | beta-GLUCAN COMPOSITION |
JP5528718B2 (en) * | 2008-03-31 | 2014-06-25 | 株式会社Adeka | Glucan composition elevation inhibitor and insulin secretagogue using β-glucan composition |
Also Published As
Publication number | Publication date |
---|---|
KR20180053361A (en) | 2018-05-21 |
WO2017047706A1 (en) | 2017-03-23 |
JP7217089B2 (en) | 2023-02-02 |
CN115475177A (en) | 2022-12-16 |
JPWO2017047706A1 (en) | 2018-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103865967B (en) | Branch alpha-glucans and the manufacturing method and purposes for generating its alpha-glucosyl transferase and they | |
TWI265790B (en) | Dehydrating agent and method for dehydrating moist article using the agent and dehydrated article obtained by the method | |
TWI303992B (en) | ||
KR20130044153A (en) | Carbohydrate composition and food and beverage producing gradual rise in blood glucose levels | |
EP1864670A1 (en) | Sucrase activity inhibitor, glucoamylase activity inhibitor and food and feed containing the same | |
TW201902365A (en) | Quality improver and its use | |
JP2010100583A (en) | Lipid metabolism improver | |
JP5442243B2 (en) | Renal disorder inhibitor | |
JP2006306831A5 (en) | ||
JP2018046762A (en) | BRANCHED α-GLUCAN MIXTURE SYRUP AND APPLICATION THEREOF | |
CA2958712C (en) | Slowly digestible, sustained-type energy supplying agent | |
KR101498592B1 (en) | The method for manufacturing starch syrup containing polydextrose | |
CN108025019A (en) | Blood glucose value raises inhibitor and the oral composition containing it | |
Zhang et al. | Max Bloc® Carb Blocker from Phaseolus Vulgaris with Ultra-high α-Amylase Inhibitory Activity for Glycemic Con-trol and Weight Management | |
CN101323847B (en) | Cyclic maltosyl maltose, cyclic maltosyl maltose synthase, method of producing the same and use thereof | |
CN100448374C (en) | Reducer of blood glucose level increase, reducer of body fat accumulation and food material |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180511 |
|
RJ01 | Rejection of invention patent application after publication |